- Changes associated with lenalidomide treatment in the gene expression profiles of patients with Del(5q)2012 | First Faculty of Medicine
- The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatmentPublication without faculty affiliation
- Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment2015 | First Faculty of Medicine
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma2012 | Faculty of Medicine in Hradec Králové
- Continuous lenalidomide treatment for newly diagnosed multiple myeloma2012 | First Faculty of Medicine
- Changes in Gene Expression Profiles in Patients with 5q- Syndrome Caused by Lenalidomide TreatmentPublication without faculty affiliation
- Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathwayPublication without faculty affiliation
- Lenalidomide treatment in myelodysplastic syndrome with 5q deletion - Czech MDS group experience2015 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
- Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome2015 | First Faculty of Medicine
- Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)2018 | First Faculty of Medicine
- Treatment strategies for myelodysplastic syndrome in 20212021 | Faculty of Medicine in Hradec Králové
- The five-year successful treatment with lenalidomide - a case report2013 | First Faculty of Medicine
- Refractory mantle cell lymphoma in elderly patient - case report2017 | Faculty of Medicine in Hradec Králové
- Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide2015 | First Faculty of Medicine
- Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment2017 | First Faculty of Medicine
- Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide2015 | Faculty of Science
- Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma2018 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
